Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Baricitinib in Systemic Lupus Erythematosus
2015-004404-35Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Remission of arthritis and/or rash at Week 24. Started Mar 2016; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-004404-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004404-35.